Company intelligence / Profile preview

LintonPharm Co., Ltd.

Ownership: Private
Development stage: Phase 3

Overview

Catumaxomab (lead product) was previously approved by EMA in 2009 for malignant ascites but voluntarily withdrawn for commercial reasons. It has received authorization from China NMPA to proceed with a Phase 3 trial for advanced gastric cancer. The company has completed enrollment for Stage 1 of a clinical trial.

Therapeutic areas: Oncology
Modalities: T cell engaging bispecific antibodiesMonoclonal antibodiesBispecific T-cell Engager (BiTE)Fusion protein
Industry: Biotech

Drug pipeline

1 asset

catumaxomab

Phase 3

Indications: Gastric cancer, Bladder cancer, Malignant ascites

Partnerships

Lindis Biotech

Beyond the preview

Go deeper on LintonPharm Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LintonPharm Co., Ltd..